Pluri Inc. is a biotechnology company. Its technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of medicine and climate change to food scarcity, animal cruelty and beyond. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is based in HAIFA, Israel.
| Revenue (Most Recent Fiscal Year) | $1.02M |
| Net Income (Most Recent Fiscal Year) | $-23.82M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 11.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2499.41% |
| Net Margin (Trailing 12 Months) | -2344.59% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -82.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.45 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 12.61M |
| Free Float | 7.17M |
| Market Capitalization | $11.73M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | 0.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 43.16% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.59% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |